
Christopher James Ferreri MD
Hematology/Oncology
Clinical Assistant Professor - Division of Plasma Cell Disorders
Join to View Full Profile
1021 Morehead Medical DrSte ACharlotte, NC 28204
Phone+1 980-442-2000
Dr. Ferreri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2020 - 2023
- Duke University HospitalResidency, Internal Medicine, 2017 - 2020
- Ohio State University College of MedicineClass of 2017
Certifications & Licensure
- NC State Medical License 2023 - 2026
- TX State Medical License 2020 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsComparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune
Journal of Clinical Oncology. 2025-05-01 - Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Ruta Brazauskas, Temitope Oloyede
Blood. 2025-04-08 - Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study.Othman Salim Akhtar, Temitope Oloyede, Ruta Brazauskas, Aimaz Afrough, Hamza Hashmi
Blood Advances. 2025-04-08
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: